College of Medicine
Srivastava Lab
Led by Arun Srivastava · Pediatrics
What we study
The lab studies parvoviruses like AAV and B19, focusing on gene therapy and vector development. They modify viral capsids and genomes to improve efficiency and reduce immune responses.
What working here is like
- Wet lab
- Mice
- Projects
- 2
- Papers
- 4
Current projects
NextGen AAV vectors
Developing high-efficiency AAV vectors for reduced doses in gene therapy.
OptY and OptX AAV vectors
Creating optimized AAV vectors for further improved efficiency and reduced immunogenicity.
Summaries are written by AI in plain language from public symposium abstracts and may be imperfect.
Recent papers, explained
- mGem: AAV, from almost a virus to an awesome vector—or is it?
2026 · mBio
Evaluates AAV vectors for gene therapy, noting their limitations and successes.
- Total and Neutralizing Antibody Seroprevalence of Hepatotropic Adeno-Associated Virus Among Healthy and Hemophilia A or B Population from India
2025 · Human Gene Therapy
Measures AAV antibody prevalence in healthy and hemophilia patients for gene therapy.
Show 2 more papersShow fewer
- Enhanced transgene expression from single-stranded AAV vectors in human cells in vitro and in murine hepatocytes in vivo
2024 · Molecular Therapy — Nucleic Acids
Shows how a part of the AAV2 vector binds to a cell's glucocorticoid receptor, boosting gene delivery in human cells.
- AAV vectors for long-term gene therapy of hemophilia B: Are we there yet?
2024 · Molecular Therapy
Reviews AAV vectors for long-term hemophilia B gene therapy, noting challenges.
Plain-language summaries are AI-written and reviewed by us; check the paper for details.
How to reach out
Arun Srivastava hasn't set up this page yet. You can also look them up in the UF directory (search “Arun Srivastava”).